# Investigating Mitogenic Mechanism and Therapeutic Efficacy of Adenosine Deaminase Knockout in Human and Murine Cardiomyocytes

> **NIH NIH F31** · DUKE UNIVERSITY · 2022 · $41,509

## Abstract

Abstract
Mammalian cardiomyocytes (CMs) in embryonic and neonatal hearts are proliferative, which allows for heart
regeneration to occur. This proliferative capacity of CMs is lost shortly after birth and in the adult hearts CMs
are largely post-mitotic, renewing at very low rates of less than 1% per year. The inability of adult CMs to
proliferate, along with the absence of resident stem cells capable of robust generation of new CMs, limit the
ability of adult mammalian hearts to self-repair following injury such as myocardial infarction (MI). Preliminary
results from my CRISPR knockout screen in cultured neonatal rat CMs show that knockout of the gene
adenosine deaminase (ADA-KO) results in robust cell cycle activation in both primary rodent and pluripotent
stem cell-derived human CMs in vitro. Follow-up RNA sequencing analysis suggests that ADA-KO alters CM
metabolism. As metabolic alterations have been shown to underlie the pro-proliferative actions of other known
cardiac mitogens, my proposed studies will determine the metabolic and molecular signaling mechanisms
governing ADA-KO mediated proliferation in human CMs. Additionally, I will test the in vitro effects of ADA-KO
on injured engineered cardiac tissues (ECTs) made using polyploid human CMs, which we have shown to be
resistant to division similarly to polyploid CMs in vivo. Furthermore, in proof-of-concept in vivo studies, I will
test therapeutic efficacy of ADA-KO in the setting of myocardial infarction by AAV delivery of ADA-KO sgRNAs
to transgenic mice with CM-specific Cas9 expression, followed by studies of cardiac proliferation and function.
When completed, these cross-species in vitro and in vivo studies will provide better understanding of the roles
of ADA in cardiac metabolism and regeneration and will create a basis for the development of novel gene
therapies for cardiac regeneration.

## Key facts

- **NIH application ID:** 10536370
- **Project number:** 1F31HL162460-01A1
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** Sophia Bunnell DeLuca
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $41,509
- **Award type:** 1
- **Project period:** 2022-09-30 → 2024-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10536370

## Citation

> US National Institutes of Health, RePORTER application 10536370, Investigating Mitogenic Mechanism and Therapeutic Efficacy of Adenosine Deaminase Knockout in Human and Murine Cardiomyocytes (1F31HL162460-01A1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10536370. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*